ICON Public Limited (NASDAQ:ICLR) Stake Lowered by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC trimmed its position in shares of ICON Public Limited (NASDAQ:ICLR) by 26.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,076 shares of the medical research company’s stock after selling 390 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in ICON Public were worth $309,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ICLR. EverSource Wealth Advisors LLC raised its stake in shares of ICON Public by 17.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after purchasing an additional 42 shares in the last quarter. Arkadios Wealth Advisors raised its position in ICON Public by 5.0% during the third quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock valued at $371,000 after acquiring an additional 62 shares in the last quarter. GAMMA Investing LLC lifted its stake in ICON Public by 50.0% in the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 87 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in ICON Public by 23.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares in the last quarter. Finally, WR Wealth Planners LLC raised its holdings in shares of ICON Public by 4.7% during the 2nd quarter. WR Wealth Planners LLC now owns 2,359 shares of the medical research company’s stock valued at $739,000 after purchasing an additional 105 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Trading Down 5.2 %

Shares of ICLR opened at $189.64 on Friday. The stock’s 50-day moving average price is $267.03 and its 200 day moving average price is $301.32. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public Limited has a 12-month low of $188.57 and a 12-month high of $347.72. The firm has a market capitalization of $15.64 billion, a price-to-earnings ratio of 21.14, a P/E/G ratio of 1.51 and a beta of 1.25.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.10 earnings per share. As a group, research analysts predict that ICON Public Limited will post 13.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on ICLR shares. Leerink Partners reduced their price target on ICON Public from $376.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Truist Financial decreased their target price on ICON Public from $363.00 to $295.00 and set a “buy” rating for the company in a research report on Monday, October 28th. JPMorgan Chase & Co. dropped their price target on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group decreased their price objective on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a report on Friday, October 25th. Finally, Robert W. Baird downgraded shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 target price on the stock. in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $304.27.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.